TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Nutriband ( (NTRB) ) is now available.
On July 9, 2025, Nutriband‘s Board of Directors approved an amendment to authorize a series of non-voting Series A Convertible Preferred Stock, increasing the authorized shares to 10,000,000. Subsequently, on August 5, 2025, Nutriband completed a stock dividend, issuing 3,008,643 shares of Series A Preferred Stock to its shareholders, with these shares held as restricted stock until eligible for conversion and registration with the SEC.
The most recent analyst rating on (NTRB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.
Spark’s Take on NTRB Stock
According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral.
Nutriband’s overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.
To see Spark’s full report on NTRB stock, click here.
More about Nutriband
Nutriband Inc. operates in the pharmaceutical industry, focusing on transdermal pharmaceutical products utilizing its AVERSA™ abuse deterrent technology.
Average Trading Volume: 79,903
Technical Sentiment Signal: Buy
Current Market Cap: $77.19M
Find detailed analytics on NTRB stock on TipRanks’ Stock Analysis page.